ArticleJournal of bone and mineral metabolism2025
Association between serum zinc concentration and fracture risk in postmenopausal women: a 9-year cohort study.
Article in Journal of bone and mineral metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Zinc deficiency in patients with type 2 diabetes increases risk of cardiovascular diseases: Tehran Lipid and Glucose Study.BMC cardiovascular disorders · 2026Article
- Serum Zinc Levels in Early Life and Risk of Elevated Carotid Intima-Media Thickness: An 8-Year Prospective Study.Cardiovascular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe association between serum zinc (SZn) concentration and fracture risk in postmenopausal women was investigated. MATERIALS AND
methodsWomen (n = 851) with a history of natural, premature, or surgical menopause who had completed data, including SZn concentrations at baseline (2009-2011), were included and followed through March 2018 for the incidence of any fracture requiring inpatient care. Potential non-linear and dose-response associations between SZn and fracture risk were assessed using a restricted cubic spline model (RCS) in Cox regression with the likelihood ratio test (LRT). Multivariable Cox proportional hazard models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of fractures across the categories of SZn [< 86, 86-135 (as reference), and ≥ 135 μg/dL].
resultsDuring a median follow-up period of 8.8 years (interquartile range: 8.1-9.2 years), 4.3% of postmenopausal women (with a mean age of 61.4 ± 8.6 years) experienced a new incident fracture. The mean of baseline SZn concentration was 113 ± 39.3 μg/dL. The LRT indicated no significant non-linear association (P = 0.176) and no evidence of a dose-response relationship (P = 0.448) between SZn and fracture risk. Using the categorical approach, the multivariable-adjusted Cox model showed that postmenopausal women with SZn concentrations below 86 μg/dL had a significantly increased risk of fracture compared to those within the reference range (86-135 μg/dL), with an HR of 2.29 (95% CI = 1.02-5.16, P = 0.044). SZn concentrations exceeding the reference range (≥ 135 μg/dL) were not associated with risk of fractures (HR = 1.47, 95% CI = 0.61-3.58).
conclusionsSuboptimal SZn levels, indicative of inadequate zinc status, may contribute to an increased risk of bone fractures in postmenopausal women.
Indexed as
Identifiers
41032115What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.